Breakthrough in HIV Research Enabled by NVIDIA GPU

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Breakthrough in HIV Research Enabled by NVIDIA GPU Accelerators

SANTA CLARA, CA--(Marketwired - May 29, 2013) - Researchers at the University of Illinois at Urbana-Champaign (UIUC) have achieved a major breakthrough in the battle to fight the spread of the human immunodeficiency virus (HIV) using NVIDIA® Tesla® GPU accelerators , NVIDIA today announced.

Featured on the cover of the latest issue of Nature , the world's most-cited interdisciplinary science journal, a new paper details how UIUC researchers collaborating with researchers at the University of Pittsburgh School of Medicine have, for the first time, determined the precise chemical structure of the HIV "capsid," a protein shell that protects the virus's genetic material and is a key to its virulence. Understanding this structure may hold the key to the development of new and more effective antiretroviral drugs to combat a virus that has killed an estimated 25 million people and infected 34 million more. 1

UIUC researchers uncovered detail about the capsid structure by running the first all-atom simulation of HIV on the Blue Waters Supercomputer . Powered by 3,000 NVIDIA Tesla K20X GPU accelerators -- the highest performance, most efficient accelerators ever built -- the Cray XK7 supercomputer gave researchers the computational performance to run the largest simulation ever published, involving 64 million atoms.

"It would have been very difficult to run a simulation of this size without the power of GPU-accelerated supercomputing in the Blue Waters system," said Klaus Schulten, professor of physics at the University of Illinois. "We started using GPU accelerators more than five years ago, and GPUs have fundamentally accelerated the pace of our research."

Designed to accelerate a broad range of scientific and technical computing applications, NVIDIA Tesla GPU accelerators are enabling researchers worldwide to make dramatic new breakthroughs across a variety of scientific domains -- including alternative energy, astrophysics, drug development, and climate research, among others. They deliver significantly higher performance and better energy efficiency as compared with CPU-based systems.

"GPUs help researchers push the envelope of scientific discovery, enabling them to solve bigger problems and gain insight into larger and more complex systems," said Sumit Gupta, general manager of the Tesla Accelerated Computing Business Unit at NVIDIA. "Blue Waters and the Titan supercomputer, the world's No. 1 open science supercomputer at Oak Ridge National Labs, are just two of many GPU-equipped systems that are enabling the next wave of real-world scientific discovery."

Capsid May Be Key to More Effective Drugs With the planned addition of more GPUs to the Blue Waters system, UIUC researchers expect to increase simulation times, providing additional insight into the structure and behavior of the HIV capsid.

The capsid has become an attractive target for the development of new antiretroviral drugs, largely due to the discovery that Rhesus monkeys have developed an immunity to HIV through a protein that disrupts capsid functioning.

The capsid is the protein cell of a virus, containing the virus's genetic material. It protects and "smuggles" the genetic material into the human host cell. Once inside, it uncoats the material and initiates the infection.

No existing HIV drug treatments are designed to target the capsid. However, by providing a better understanding of the structure of the HIV capsid, pharmacologists have a wealth of new information to develop new and potentially more effective antiviral HIV drugs.

About NVIDIA Tesla GPUs NVIDIA Tesla GPUs are massively parallel accelerators based on the NVIDIA CUDA® parallel computing platform and programming model. Tesla GPUs are designed from the ground up for power-efficient, high performance computing, computational science and supercomputing, delivering dramatically higher application acceleration for a range of scientific and commercial applications than a CPU-only approach.

To learn more about CUDA or download the latest version, visit the CUDA website . Follow us on Twitter at @NVIDIATesla .

About NVIDIA Since 1993, NVIDIA ( NASDAQ : NVDA ) has pioneered the art and science of visual computing. The company's technologies are transforming a world of displays into a world of interactive discovery -- for everyone from gamers to scientists, and consumers to enterprise customers. More information at http://nvidianews.nvidia.com and http://blogs.nvidia.com .

(1) Source: http://www.who.int/mediacentre/factsheets/fs3...index.html

Certain statements in this press release including, but not limited to, statements as to: the impact and benefits of NVIDIA Tesla GPUs and NVIDIA Tesla GPU accelerators are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the reports NVIDIA files with the Securities and Exchange Commission, or SEC, including its Form 10-Q for the fiscal period ended April 28, 2013. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2013 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, Tesla and CUDA are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

For further information, contact: George Millington NVIDIA Public Relations (408) 562-7226 gmillington@nvidia.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 15

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 11

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 17

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 22

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 20

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 23

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into Stella-Jones Conference Call for Q3 Results

Updated Category News Views 70

Upcoming Conference Call for Stella-Jones Inc. Stella-Jones Inc. (TSX: SJ), a prominent player in the manufacturing of pressure-treated wood products, is set to hold a significant conference call to discuss its third quarter results. Details of the Conference Call The conference call is open to investors, analysts, and all interested parties. It will take place on...

Continue Reading
Total Voting Rights Announcement for Northern Venture Trust

Updated Category News Views 75

Update on Total Voting Rights Northern Venture Trust PLC has released a key update concerning its total voting rights. In line with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, the Company is informing the market about its present capital structure. Overview of Ordinary Shares As per the latest information, Northern Venture Trust PLC's...

Continue Reading
Northrop Grumman Faces Investor Scrutiny Amid Financial Decline

Updated Category News Views 431

Investor Concerns Around Northrop Grumman Investors holding shares in Northrop Grumman Corporation (NYSE: NOC) are facing critical developments as they are encouraged to evaluate their positions in light of recent financial disclosures and ongoing investigations by legal entities. This alert revolves around Northrop Grumman's recent performance and future implications...

Continue Reading
Nature's Sunshine Welcomes Katie May to Board Leadership

Updated Category News Views 420

Nature's Sunshine Embraces New Leadership with Katie A. May Nature's Sunshine Products, Inc. is thrilled to announce that Katie A. May has joined its board of directors, marking a significant step in enhancing leadership and direction within the company. With a rich background in ecommerce and logistics, Katie's new role reflects the company's commitment to further...

Continue Reading
NewAmsterdam Pharma Announces Participation in Key Investor Conferences

Updated Category News Views 79

NewAmsterdam Pharma to Attend Investor Conferences NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a leading biopharmaceutical firm committed to creating innovative oral medications designed to reduce low-density lipoprotein (LDL) cholesterol levels for individuals at risk of cardiovascular disease (CVD). The company is preparing for a series of upcoming investor...

Continue Reading